VLA 0.00% $1.75 viralytics limited

27.1 million cr, page-25

  1. 4,695 Posts.
    lightbulb Created with Sketch. 72
    Thx to jasonobrien1984 for this link

    "23 Australian Biotech Stocks To Watch This Year
    CHRIS PASH TODAY AT 12:34 PM 4
    Biotech

    The biotechnology sector in Australia raised a collective $739.1 million in 2013 and some ASX-listed companies saw many-fold surges in share prices. The sector has a combined market capitalisation of around $50 billion.

    The biotech sector in the US has outperformed the market over the past year. Some see signs of yet another biotech bubble. But as The Economist notes this week, although biotechs have undergone cycles of boom and bust for four decades, there are some signs – as smaller companies feed R&D to bigger ones, and as scientists start to reap the benefits from the mapping of the human genome – that this cycle may be different.

    Business Insider Australia asked Mark Pachacz, Research Principal at Bioshares, Scott Power, Senior Analyst at Morgans and Matthijs Smith, Senior Analyst, Canaccord Genuity, to name the biotech companies to watch in 2014.

    Innate Immunotherapeutics and Impedimed were picked by all three analysts. Tissue Therapies, Viralytics and Cogstate were included in top ten lists by two of the three analysts.

    Viralytics (VLA): (Bioshares, Canaccord) Using a virus to kill cancer. Very good Phase II data emerging. Just raised $27 million. A comparable company, Biovex, was acquired by Amgen in a deal worth close to USD 1 billion. Viralytics’ data is as good as Biovex/Amgen, but about 2 years behind."


    http://www.businessinsider.com.au/23-australian-biotech-stocks-to-watch-this-year-2014-2

 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.